FilingSEC EDGAR8-K
Opus Genetics Announces Positive Interim Results for OPGx-BEST1 Phase 1/2 Trial
· SEC accepted
StagePhase 1/2
Filing content
The company reported positive interim results from the low-dose cohort of its Phase 1/2 trial for OPGx-BEST1 and confirmed alignment with the FDA on potential pivotal endpoints.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…